The Efficacy of Aloe vera Gel in Treatment of Oral Lichen Planus

Sofia Sid Ahmed¹, Laila M. Gadalla², Samah H. Elmeadawy³, Farid Badria⁴

¹Department of Oral Medicine and Periodontology, Researcher in Faculty of Dentistry, Mansoura University, Mansoura, Egypt, ²Department of Oral Medicine and Periodontology, Faculty of Dentistry, Mansoura University, Mansoura, Egypt, ³Department of Oral Medicine and Periodontology, Faculty of Dentistry, Mansoura University, Mansoura, Egypt, ⁴Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

Abstract

Background: Aloe vera (AV) gels with different concentrations are available in the market. In this study, we evaluate the efficacy of AV gel with two different concentrations in the treatment of oral lichen planus (OLP) compared with placebo.

Materials and Methods: A total of 21 females suffering from the clinical signs and symptoms of OLP were grouped into Group (I) patients receiving AV gel divided into two subgroups, subgroup (A) received AV 70% concentration (7 patients) and subgroup)B) received AV 90% concentration (7 patients) and Group (II) control group received placebo (7 patients).

Results: There was no statistically significant difference between ulcer sizes at all points of follow-up in Egyptian and Australian AV compared to placebo. The degree of change was higher in Egyptian than Australian AV regarding size, erythema, reticulation, and total area of lesion. However, there was no statistically significant difference between two types of treatment as regards all measured parameters (P > 0.05).

Conclusions: AV gel whether Egyptian or Australian is statistically significantly more effective than placebo in inducing marked improvement clinically of OLP. Therefore, AV gel can be considered a safe alternative treatment for patients with OLP.

Clinical Significance: AV gel can be considered a safe alternative treatment for patients with OLP.

Keywords: Aloe vera, erythema, oral lichen planus, placebo

Introduction

Oral lichen planus (OLP) is a chronic inflammatory disease characterized by abnormally keratinized oral mucosa and band-like T-cell infiltration in the upper lamina propria. Consequently, it is referred to as a potentially malignant disorder by the World Health Organization working group. Clinically, OLP is classified into seven forms: Atrophic, bullous, erosive, popular, pigmented, plaque-like, or reticular. The patients with reticular lesions, the most common form, generally have no clinical symptoms, while atrophic, bullous, and erosive lesions cause pain, ranging from mild to severe. Notably, erosive OLP shows a significantly higher rate of malignant transformation than non-erosive OLP.[1]

The lichen planus antigen is unknown, although it may be a self-peptide (or altered self-peptide). The expression or unmasking of the lichen planus antigen may be induced by drugs (lichenoid drug reaction), contact allergens in dental restorative materials or toothpastes (contact hypersensitivity reaction), mechanical trauma (Koebner phenomenon), viral infection, or other unidentified agents.[2]

There is no fully resolutive and effective treatment the management strategy focusing on the use of drugs that counter tissue inflammation and the underlying immunological mechanisms. Some topical corticosteroid therapies may predispose the patient to oral candidiasis. However, this condition is rarely if ever symptomatic, and it generally does not complicate healing of the erosions related to OLP. Topical antymycotics (e.g., nystatin and amphotericin) may be prescribed when an infection is present.[3]

Erosive OLP that is recalcitrant to topical corticosteroids may respond to topical tacrolimus.[4] Other potential therapies for recalcitrant OLP include hydroxychloroquine, dapsone, systemic corticosteroids, and topical and systemic retinoids.[5] The main inconvenience of these treatments is represented by the side effects including insomnia, nervousness, fluid retention, electrolyte imbalance, hyperglycemia, osteoporosis, nephrotoxicity, gingival hyperplasia, nausea, and headache.[6]
Due to these side effects, the possibility of prolonged treatment with steroids, and the fact that the disease process could still last for years, an alternative therapy is desirable. Moreover, topical corticosteroids are the mainstay of medical treatment of OLP, although rarely, corticosteroids may be administered intralesionally or systemically. Topical treatment is a good choice because of its less harmful side effects.

Studies have demonstrated that AV has an important therapeutic use in the management of oral lesions such as oral submucous fibrosis, radiation-induced mucositis, burning mouth syndrome, xerostomia, and recurrent aphthous ulcers. AV was expiated from Australia with concentration 90% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose. The placebo gel expiated from Australia with concentration 90% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose. It is consisted of 70% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose. The placebo gel expiated from Australia with concentration 90% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose.

Each patient was instructed to apply the AV twice daily by finger/cotton tip application on dry lesion after meals without eating for at least ½ h to obtain better absorption.

Lesions were measured with a flexible, transparent grid divided into calibrated squares of 1 mm², and a thin indelible, ink marker. The grid was placed over the lesion, and area of ulceration, erythema, and reticulation were traced with the ink marker. Quantitative measurements of the lesion were calculated from the grid by collecting the number of squares by 1 mm².

The pain was scored by visual analog scale. Patients were asked to score their intensity of pain at each visit as follow: 0 = no pain, 1 = mild pain, 2 = moderate pain, and 3 = severe pain.

The aim of the study is to evaluate the efficacy of AV gel in the treatment of OLP compared with placebo.

Materials and Methods

A total of 21 females from those attending to the Department of Oral Medicine and Periodontology, Faculty of Dentistry, Mansoura University, were included in the study. The patients were suffering from the clinical signs and symptoms of OLP. The first (patients) group received AV gel divided into two subgroups: (A) 7 patients received AV 70% and (B) 7 patients received AV 90%. The second (control) group included seven patients receiving placebo [Table 1].

Two Aloe vera (AV) types were used: AV manufactured locally by Faculty of Pharmaceutical Sciences of Mansoura University. It is consisted of 70% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose. AV was expiated from Australia with concentration 90% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose. The placebo gel expiated from Australia with concentration 90% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose.

Materials and Methods

A total of 21 females from those attending to the Department of Oral Medicine and Periodontology, Faculty of Dentistry, Mansoura University, were included in the study. The patients were suffering from the clinical signs and symptoms of OLP. The first (patients) group received AV gel divided into two subgroups: (A) 7 patients received AV 70% and (B) 7 patients received AV 90%. The second (control) group included seven patients receiving placebo [Table 1].

Two Aloe vera (AV) types were used: AV manufactured locally by Faculty of Pharmaceutical Sciences of Mansoura University. It is consisted of 70% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose. AV was expiated from Australia with concentration 90% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose. The placebo gel expiated from Australia with concentration 90% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose.

Each patient was instructed to apply the AV twice daily by finger/cotton tip application on dry lesion after meals without eating for at least ½ h to obtain better absorption.

Lesions were measured with a flexible, transparent grid divided into calibrated squares of 1 mm², and a thin indelible, ink marker. The grid was placed over the lesion, and area of ulceration, erythema, and reticulation were traced with the ink marker. Quantitative measurements of the lesion were calculated from the grid by collecting the number of squares by 1 mm².

The pain was scored by visual analog scale. Patients were asked to score their intensity of pain at each visit as follow: 0 = no pain, 1 = mild pain, 2 = moderate pain, and 3 = severe pain.

The aim of the study is to evaluate the efficacy of AV gel in the treatment of OLP compared with placebo.

Materials and Methods

A total of 21 females from those attending to the Department of Oral Medicine and Periodontology, Faculty of Dentistry, Mansoura University, were included in the study. The patients were suffering from the clinical signs and symptoms of OLP. The first (patients) group received AV gel divided into two subgroups: (A) 7 patients received AV 70% and (B) 7 patients received AV 90%. The second (control) group included seven patients receiving placebo [Table 1].

Two Aloe vera (AV) types were used: AV manufactured locally by Faculty of Pharmaceutical Sciences of Mansoura University. It is consisted of 70% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose. AV was expiated from Australia with concentration 90% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose. The placebo gel expiated from Australia with concentration 90% AV mucilage, sorbitol, potassium sorbate, sodium metabisulfite, and hydroxyethyl cellulose.

Each patient was instructed to apply the AV twice daily by finger/cotton tip application on dry lesion after meals without eating for at least ½ h to obtain better absorption.

Lesions were measured with a flexible, transparent grid divided into calibrated squares of 1 mm², and a thin indelible, ink marker. The grid was placed over the lesion, and area of ulceration, erythema, and reticulation were traced with the ink marker. Quantitative measurements of the lesion were calculated from the grid by collecting the number of squares by 1 mm².

The pain was scored by visual analog scale. Patients were asked to score their intensity of pain at each visit as follow: 0 = no pain, 1 = mild pain, 2 = moderate pain, and 3 = severe pain.

Test of significance was done: P > 0.05 = non-significant, P < 0.05* = significant, and P < 0.01** = highly significant.

Results

There was no statistically significant difference between ulcer sizes at all points of follow-up in Egyptian and Australian AV compared to placebo [Figure 1 and Table 2]. Erythema score among study groups at different times the erythema score decreased in both types of AV. There was no statistically significant difference between erythema at 2 and 4 weeks of follow-up in Egyptian (Group I/A) and Australian AV (Group I/B) compared to placebo. However, statistically significant difference was found between Australian AV and placebo treatment at final visit (P < 0.05) [Figure 2 and Table 3]. The mean reticulations decreased in both Egyptian and Australian groups at 2, 4, 6, and 8 weeks with a statistically significant difference were found between for Egyptian and Australian AV compared to placebo treatment at 4 and 6 weeks visits (P < 0.05) [Table 4]. The mean total area of lesion decreased in both Egyptian and Australian groups at 2, 4, 6, and 8 weeks with a statistically significant difference was found between for Egyptian AV compared to placebo treatment at 6 and 8 weeks visits (P < 0.05) [Table 5]. Pain score evaluation decreased in both Egyptian at the 6th week and Australian groups at 4, 6, and 8 weeks with a statistically significant difference (P < 0.05) [Table 6]. The degree of change was higher in Egyptian than Australian AV regarding size, erythema, reticulation, and total area of lesion. However, there was no statistically significant difference between two types of treatment as regards all measured parameters (P > 0.05) [Figure 3 and Table 7].

| Table 1: Mean age of studied groups | Intervention | Egyptian AV (70%) | Australian AV (90%) | Placebo (n=5) | P |
|------------------------------------|-------------|------------------|---------------------|--------------|---|
| Age mean±SD                        | 53.8±4.4    | 50.1±3.8         | 57.6±13.3           | 0.2          |

There was no statistically significant difference between study groups as regards age. SD: Standard deviation, AV: Aloe vera

Figure 1: Case 1 (a) shows erosive type of lichen planus on the left buccal mucosa of 55-year-old women with 2 years duration before treatment. (b) After treatment with Egyptian Aloe vera

Figure 2: Case 2 (a) reticular type of lichen planus on the right buccal mucosa before treatment. (b) After treatment with Egyptian Aloe vera
Table 2: Size of ulceration among study groups at different times

| Timing of follow-up | Egyptian AV (Group I/a) | Australian AV (Group I/b) | Placebo (Group II) | Significance |
|---------------------|--------------------------|---------------------------|-------------------|--------------|
|                     | (n=7)                    | (n=7)                     | (n=5)             | P1 | P2 | P3 |
| Baseline            | 70 (45–200)              | 60 (39–90)                | 50 (30–78)        | 0.2 | 0.1 | 0.2 |
| 2 weeks             | 69 (40–200)              | 55 (36–76)                | 50 (30–80)        | 0.5 | 0.2 | 0.4 |
| (2nd visit)         |                          |                           |                   |    |    |    |
| 1 month             | 60 (25–110)              | 35 (23–65)                | 50 (30–78)        | 0.4 | 0.8 | 0.5 |
| (3rd visit)         |                          |                           |                   |    |    |    |
| 2 months            | 45 (15–69)               | 35 (10–45)                | 50 (33–80)        | 0.1 | 0.4 | 0.2 |
| (4th visit)         |                          |                           |                   |    |    |    |
| 5th (visit)         | 35 (0–70)                | 35 (0–50)                 | 50 (35–80)        | 0.04* | 0.1 | 0.1 |

P1: Compression between three groups, P2: Compression between Egyptian AV and control group, P3: Compression between Australian AV and control group, P4: Compression between baseline with each follow-up visit.

Table 3: Erythema score among study groups at different times (mean±SD)

| Timing of follow-up | Egyptian AV | Australian AV | Placebo | Significance |
|---------------------|-------------|---------------|---------|--------------|
|                     | n=7         | n=7           | n=5     | P1 | P2 | P3 |
| Baseline            | 129.3±58.7  | 94.14±33.11   | 102.2±32.4 | 0.9 | 0.6 | 0.3 |
| 2 weeks (2nd visit) | 122.14±59.3 | 83.7±28.5     | 101.8±33.03 | 0.7 | 0.8 | 0.2 |
| P1 value            | 0.2         | 0.02*         | 0.3     |    |    |    |
| 4 weeks (3rd visit) | 97.14±52.7  | 65.0±17.5     | 102.2±32.4 | 0.1 | 0.9 | 0.1 |
| P1 value            | 0.02*       | 0.01*         | ---     |    |    |    |
| 6 weeks (4th visit) | 69.14±28.07 | 49.3±17.6     | 102.0±32.9 | 0.05 | 0.2 | 0.01 |
| P1 value            | 0.02*       | 0.01*         | 0.7     |    |    |    |
| 8 weeks (5th visit) | 60.0±37.7   | 34.3±17.0     | 103.2±31.9 | 0.01* | 0.15 | 0.01 |
| P1 value            | 0.03*       | 0.004*        | 0.3     |    |    |    |

P1: Compression between three groups, P2: Compression between Egyptian AV and control group, P3: Compression between Australian AV and control group, P4: Compression between baseline with each follow-up visit. SD: Standard deviation. AV: Aloe vera

Discussion

In this study, women only were chosen to get rid of inherent variation in the immune responses in females versus males, which might account for the higher prevalence of autoimmune diseases among females. It has recently been shown that females have a stronger TH1 immune response mediated by interferon gamma. Several animal studies have shown that female mice have greater antibody production capacity, increased cell-mediated responses, and increased production of interferon gamma, interleukin (IL)-1, and IL-6 compared to males. Human vaccination studies have confirmed similar patterns.[11]
As regarded to size of ulceration, reticulation, and erythema of both types of AV, they were decrease significantly after 6 and 8 weeks. However, the size of ulceration, reticulation, and erythema of placebo was same. The authors confirmed that the AV is more efficient than placebo in ulceration, reticulation, and erythema reduction. Choonhakarn et al.[7] stated that the difference is statistically significant, while Salazar-Sanchez et al.[12] stated that it is insignificant. Another study done by Mansourian et al.[13] and Reddy et al.[14] demonstrated that AV and triamcinolone acetonide (TA) had comparable effect in the ulceration, reticulation, and erythema reduction with no statistically significant difference and both medications lead to significant reduction in ulceration, reticulation, and erythema.

The improvement of ulceration, reticulation, and erythema can be explained by that AV can inhibit the inflammatory process by its interfering actions on the arachidonic acid pathway through cyclooxygenase. Moreover, the healing powers of AV through high-molecular-weight polypeptide constituent from the gel demonstrated a healing effect on excisional wounds in rats.[15] Yagi et al.[16] reported that AV gel contains a glycoprotein with cell proliferating-promoting activity, while Davis et al.[17] noted that AV increasing blood supply, which increased oxygenation as result. As regarded to erythema score among study groups at different times, decreased in both types of AV. However, final follow-up

### Table 4: Reticulation among study groups at different times (mean±SD)

| Timing of follow-up | Egyptian AV | Australian AV | Placebo (Group II) | P     |
|---------------------|-------------|---------------|-------------------|-------|
|                     | n=7         | n=7           | n=5               |       |
| Baseline            | 144.3±60.2  | 128.6±34.3    | 183.2±50.4        | 0.07  |
| 2 weeks (2nd visit) | 143.7±64.7  | 115.0±30.9    | 184.±49.2         | 0.03  |
|                     | 0.8         | 0.006*        | 0.7               |       |
| 4 weeks (3rd visit) | 111.4±60.6  | 87.7±28.4     | 183.2±50.4        | 0.004 |
|                     | 0.01        | <0.001*       | --                |       |
| 6 weeks (4th visit) | 87.14±50.3  | 70.14±34.6    | 185.2±48.9        | <0.001|
|                     | 0.02        | <0.001*       | 0.3               |       |
| 8 weeks (5th visit) | 15          | 50            | 176               | 0.005 |
|                     | 0.03        | 0.01          | 0.1               |       |

P: Compression between three groups, P1: Compression between Egyptian AV and control group, P2: Compression between Australian AV and control group, P3: Compression between baseline with each follow-up visit. SD: Standard deviation, AV: Aloe vera

### Table 5: Total area of lesion in mm at different times (mean±SD)

| Timing of follow-up | Egyptian AV | Australian AV | Placebo (Group II) | P     |
|---------------------|-------------|---------------|-------------------|-------|
|                     | n=7         | n=7           | n=5               |       |
| Baseline            | 345.7±87.6  | 286.14±55.5   | 336.0±78.4        | 0.2   |
| 2 weeks (2nd visit) | 352.14±111.6| 256.8±45.8    | 336±82.2          | 0.1   |
|                     | 0.7         | 0.004*        | 1                 |       |
| 4 weeks (3rd visit) | 267.14±96.04| 194.14±45.0   | 338±82.3          | 0.006 |
|                     | 0.01*       | <0.001*       | 0.3               |       |
| 6 weeks (4th visit) | 209.7±111.8 | 150.8±56.3    | 338.8±79.6        | 0.002 |
|                     | 0.02*       | <0.001*       | 0.3               |       |
| 8 weeks (5th visit) | 120         | 125           | 346.4±82.5        | 0.003 |
|                     | 10–380      | 0–270         | 350               |       |
|                     | 270–470     |               |                   |       |

P: Compression between three groups, P1: Compression between Egyptian AV and control group, P2: Compression between Australian AV and control group, P3: Compression between baseline with each follow-up visit. SD: Standard deviation, AV: Aloe vera
Table 6: Pain evaluation among study groups at different times

| Timing of follow-up | Egyptian AV (Group I/a) | Australian AV (Group I/b) | Placebo (Group II) | P | P | P |
|---------------------|--------------------------|----------------------------|-------------------|---|---|---|
|                     | Mean±SD                  | Mean±SD                    | P                 | P | P | P |
| Baseline            | 3±0.3-3                  | 3±3-Feb                    | 3±3-Feb           | 0.5 | 0.7 | 0.4 |
| 2 weeks             | 3±3-Feb                  | 3±3-Feb                    | 3±3-Feb           | 0.7 | 0.5 | 0.4 |
| (2nd visit)         | 3±3-Feb                  | 3±3-Feb                    | 3±3-Feb           | 1.0 | 0.8 | 0.6 |
| P                   | 0.1                      | 0.3                        | 1                 | 0.4 | 0.07 | 0.05 |
| 4 weeks             | 3±2                      | 3±3-Feb                    | 3±3-Feb           | 0.03 | 0.07 | 0.05 |
| (3rd visit)         | 3±3-Feb                  | 3±3-Feb                    | 3±3-Feb           | 0.04 | 0.2 | 0.05 |
| P                   | 0.4                      | 0.04*                      | 1                 | 0.02* | 1.0 | 0.5 |
| 6 weeks             | 2±2                      | 3±3                        | 3±3-Feb           | 0.03 | 0.07 | 0.05 |
| (4th visit)         | 0–3                      | 2-Jan                      | 3±3-Feb           | 0.02* | 0.02* | 0.2 |
| P                   | 0.3                      | 0.02*                      | 1                 | 0.01 | 0.2 | 0.05 |
| 8 weeks             | 2±1                      | 3±3                        | 3±3-Feb           | 0.02* | 0.2 | 0.05 |
| (5th visit)         | 0–3                      | 0–2                        | 3-Feb             | 0.2 | 0.02* | 0.5 |
| (Range)             | 0.2                      | 0.02*                      | 1                 | 0.02* | 0.2 | 0.05 |

SD: Standard deviation, AV: Aloe vera

Table 7: Average degree of change after treatment in Australian and Egyptian AV

| Intervention change type | Egyptian AV (Group I/a) | Australian AV (Group I/b) | Placebo (Group II) | P |
|--------------------------|--------------------------|----------------------------|-------------------|---|
| Size of ulceration in mm (Median) | 70                      | 60                        | 60                | 0.6 |
| Erythema (Mean)          | 128.7                    | 93.7                      | 93.7              | 0.09 |
| Reticulation (Mean)      | 143.9                    | 128.2                     | 128.2             | 0.5 |
| Total area of lesion (Mean) | 345.2                    | 285.8                     | 285.8             | 0.2 |
| Pain severity (Median)   | 1                       | 0                         | 0                 | 0.5 |

AV: Aloe vera

visit, erythema was less in Australian AV (34.3 ± 17.0) compared to Egyptian one (60.0 ± 37.7). This decrease in erythema score may be explained by increase in concentration of the Australian group (90%) compared to the Egyptian group (70%).

Both types of AV show decrease in pain perception as compared to placebo. This result was in agreement with both Choonhakarn et al.\(^7\) and Salazar-Sanchez et al.\(^12\) studies who confirmed that the AV is more efficient than placebo in pain reduction. Choonhakarn et al.\(^7\) stated that the difference is statistically significant, while Salazar-Sanchez et al.\(^12\) stated that it is insignificant. Mansourian et al.\(^13\) and Reddy et al.\(^14\) demonstrated that AV and TA had comparable effect in the pain reduction with no statistically significant difference and both medications lead to significant reduction in pain.

The decreased pain perception with AV can be explained by decrease in the size of ulceration showed in both AV groups. Moreover, AV shows to breakdown bradykinin an inflammatory substance that induced the pain.\(^15\) Regards to the pain there was decrease significantly in Australian AV after 4 weeks, while in Egyptian AV pain was decreased after 6 weeks. That is explained by that the pain is respond well to high concentration of AV.

Patients receiving AV gel reported burning and mild itching at the lesion within the 1st week, but symptoms spontaneously disappeared when patients continued to use the gel. No significant complaint was reported in placebo group.

**Conclusion**

AV gel whether Egyptian or Australian is statistically significantly more effective than placebo in inducing marked improvement clinically of OLP. Therefore, AV gel can be considered a safe alternative treatment for patients with OLP.

**References**

1. Bombeccari GP, Guzzi G, Tettamanti M, Gianni AB, Baj A, Pallotti F, et al. Oral lichen planus and malignant transformation: A longitudinal cohort study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:328-34.
2. Pendyala G, Joshi S, Kalburge J, Joshi M, Tejani A. Oral lichen planus: A report and review of an autoimmune-mediated condition in gingiva. Compend Contin Educ Dent 2012;33:102-8.
3. Sandhu SV, Sandhu JS, Bansal H, Dua V. Oral lichen planus and stress: An appraisal. Contemp Clin Dent 2014;5:352-6.
4. Shilpa PS, Kaul R, Bhat S, Sanjay CJ, Sultana N. Topical tacrolimus in the management of oral Lichen planus: Literature
review. J Calif Dent Assoc 2014;42:165-70.
5. López-Jornet P, Camacho-Alonso F. Quality of life in patients with oral lichen planus. J Eval Clin Pract 2010;16:111-3.
6. Ali S, Wahbi W. The efficacy of Aloe vera in management of oral lichen planus: A systematic review and meta-analysis. Oral Dis 2017;23:913-8.
7. Choonhakarn C, Busaracome P, Sripaandikulkhai B, Sarakarn P. The efficacy of Aloe vera gel in the treatment of oral lichen planus: A randomized controlled trial. Br J Dermatol 2008;158:573-7.
8. George D, Bhat S, Antony B. Comparative evaluation of antimicrobial efficacy of Aloe vera tooth gel and two popular commercial toothpastes. An in vitro study. Gen Den 2009;75:238-41.
9. Wadhawan R, Khan S, Solanki G, Sabir S. Aloe vera: Boon in dentistry. Int J Pharm Res Rev 2014;4:147-51.
10. Harpenau LA, Plemons JM, Rees TD. Effectiveness of a low dose of cyclosporine in the management of patients with oral erosive lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:161-7.
11. Airas L. Hormonal and gender-related immune changes in multiple sclerosis. Acta Neurol Scand 2015;132:62-70.
12. Salazar-Sanchez N, Lopez-Jornet P, Camacho-Alonso F, Sanchez-Siles M. Efficacy of topical Aloe vera in patients with oral lichen planus: A randomized double-blind study. J Oral Pathol Med 2010;39:735-40.
13. Mansourian A, Momen-Heravi F, Saheb-Jamee M, Esfahani M, Khalilzadeh O, Momen-Beitollahi J, et al. Comparison of Aloe vera mouthwash with triamcinolone acetonide 0.1% on oral lichen planus: A randomized double-blinded clinical trial. Am J Med Sci 2011;342:447-51.
14. Reddy RL, Reddy RS, Ramesh T, Singh TR, Swapna LA, Laxmi NV, et al. Randomized trial of Aloe vera gel vs triamcinolone acetonide ointment in the treatment of oral lichen planus. Quintessence Int 2012;43:793-800.
15. Neena IE, Ganesh E, Poornima P, Korishettar R. An ancient herb Aloe vera in dentistry: A review. J Oral Res Rev 2015;7:25-30.
16. Yagi A, Egusa T, Arase M, Tanabe M, Tsuji H. Isolation and characterization of the glycoprotein fraction with a proliferation-promoting activity on human and hamster cells in vitro from Aloe vera gel. Planta Med 1997;63:18-21.
17. Davis RH, Leitner MG, Russo JM, Byrne ME. Anti-inflammatory activity of Aloe vera against a spectrum of irritants. J Am Podiatr Med Assoc 1989;79:263-76.
18. Sundarkar P, Govindwar R, Nyamati SB, Alladwar N, Thombre V, Soni A, Raj A. Use of Aloe vera in dentistry. J Indian Acad Oral Med Radiol 2011;23:389-91.

How to cite this article: Ahmed SS, Gadalla LM, Elmeadawy SH, Badria F. The efficacy of Aloe vera gel in treatment of oral lichen planus. Int Dent Med J Adv Res 2018;4:1-6.